SHUTTLE PHARMACEUTICALS HOLDINGS INC (SHPH)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$3.50+0.57%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · SHPH
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry Into A Material Definitive Agreement. On August 31, 2026, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) and United Dogecoin Inc. (“United Dogecoin”), a wholly-owned subsidiary of the Company as a result of the consummation on May 6, 2026 of that certain transaction contemplated by the Agreement and Plan of Merger dated April 30, 2026 (the “Merger Agreement”), by and among the Company, United Dogecoin and Shuttle Merger Sub, Inc., entered into a First Amendment to Merger Agreeme…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 28, 2026, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2026 (the “Form 10-Q”) with the Securities and Exchange Commissi…
of the Original 8-K, and incorporated by reference into
of Form 8-K. This Current Report on Form 8-K/A amends the Original 8-K solely to amend and include Item 2.01, Item 9.01(a) and Item 9.01(b), to reflect that the transactions contemplated by the Merger Agreement are not significant and accordingly the historical and pro forma financial information required under those items are not applicable. There are no other modifications or updates to any of the information made in the Original 8-K.
of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in
Material Modification to Rights of Security Holders. To the extent required by
Completion of Acquisition or Disposition of Assets. The disclosure required by this Item in connection with the Closing and included in
Co-Chief Executive Officer — Ryan Trasolini: Appointment of Ryan Trasolini as Co-Chief Executive Officer in connection with the Merger.
Unregistered Sales of Equity Securities. The disclosure set forth above in
Entry Into A Material Definitive Agreement. Merger Agreement General Description of the Merger Agreement On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shutt…
by reference. The issuance of the Merger Consideration and the offer, sale and issuance of the Securities have not been registered under the Securities Act of 1933, as amended (the “ Securities Act ”), in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act.
Entry Into A Material Definitive Agreement. Merger Agreement General Description of the Merger Agreement On April 30, 2026, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”). The transactions contemplat…
Entry into a Material Definitive Agreement. On March 5, 2026, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) priced its recently announced public offering (the “Offering”) of 2,238,800 shares of the Company’s common stock par value $0.00001 per share (the “Common Stock”), and pre-funded warrants to purchase up to 4,761,200 shares of Common Stock (the “Pre-Funded Warrants”) for aggregate gross proceeds of approximately $3.5 million, before deducting placement agent fees and other offer…
Results of Operations and Financial Condition. On February 11, 2026, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) filed a registration statement on Form S-1 disclosing certain preliminary estimated unaudited financial results for the full year ended December 31, 2025. The text of the disclosure of those preliminary estimated unaudited financial results is included below. Preliminary Estimated Unaudited Financial Results for the Year Ended December 31, 2025 Set forth below are prelim…
The filing details an amendment to a consulting agreement, not a management change.
Director — Sachin Pathigoda: Mr. Sachin Pathigoda resigned from his position as a director of the Board.
Entry into a Material Definitive Agreement. On December 23, 2025 (the “ Effective Date ”), Shuttle Pharmaceuticals Holdings, Inc. (the “ Company ”) entered into a First Amendment (the “ Amendment ”) to Asset Purchase Agreement (the “ Agreement ”) with 1563868 B.C. Ltd., a Canadian limited corporation and the Company’s wholly owned subsidiary (“ Purchaser ”), 1542770 BC Ltd., a Canadian limited corporation (“ Seller ”), and ZhiTian (Andy) Zhang, an individual residing in Vancouver, Canada (“ S…
Unregistered Sales of Equity Securities. The information set forth under in
Chief Financial Officer — Timothy Lorber: Mr. Lorber resigned as Chief Financial Officer and will be replaced by Christopher Cooper, who is currently the Interim Chief Executive Officer.
Entry into a Material Definitive Agreement. On November 20, 2025 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “ Agreement ”) with 1563868 B.C. Ltd., a Canadian limited corporation and the Company’s wholly owned subsidiary (“ Purchaser ”), 1542770 BC Ltd., a Canadian limited corporation (“ Seller ”) and Zhitian (Andy) Zhang, an individual residing in Vancouver, Canada (“ Seller Guarantor ”). Pursuant to the terms a…
Completion of Acquisition or Disposition of Assets. The disclosure set forth under
Unregistered Sales of Equity Securities. The information set forth under in
Termination of a Material Definitive Agreement. The information set forth above under
Entry into a Material Definitive Agreement. As previously disclosed by the Company in its Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 21, 2025, on October 15, 2025, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) received a letter from Theradex Systems, Inc. (“Theradex”), providing written notice of termination of the master agreement, dated November 1, 2018 (the “Master Agreement”), between Shuttle Pharmaceuticals, Inc. (th…
contains “forward-looking” statements and estimates, including anticipated winddown costs. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether the Company will successfully winddown the Clinical Trials and other risks detailed in the “Risk Factors” section of the Company’s most recent periodic report filed with the SEC. These statements represent the Company’s estimates and assumptions only as of the date…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.